Across our alfaCAR-TTM technology platform, Alfa Cytology is actively seeking collaboration opportunities to license our innovative preclinical CAR-T research pipeline or co-develop next-generation CAR-T cell therapy candidates. Leveraging our state-of-the-art cell engineering capabilities and robust preclinical validation systems, our objective is to develop CAR-T therapies that exhibit superior specificity and enhanced cytotoxic efficiency, thereby accelerating the advancement of novel cellular immunotherapy products.
Should you have an interest in our projects, we invite you to contact us to explore potential opportunities for collaboration. We are eager to collaborate with you to advance the promising future of cell therapy.
| Projects | Modalities | Disease | Indication | Discovery | Preclinical | IND | Phase I | Phase II | Phase III |
| CAR-007 | alfaCAR-T | Neuroblastoma | Solid Tumors | ||||||
| CAR-016 | alfaCAR-T | Lymphoma | Hematologic Malignancies | ||||||
| CAR-027 | alfaCAR-T | Breast Cancer | Solid Tumors |
For research use only.
As a pioneer in alfaCAR-T cell therapy development, Alfa Cytology delivers comprehensive preclinical solutions to advance next-generation cancer immunotherapies. Our integrated technology platform combines state-of-the-art alfaCAR-TTM design capabilities with precision engineering and multi-dimensional characterization systems, accelerating translational research from concept to preclinical application. Through innovative targeting strategies and optimized construct development, we empower researchers to overcome key challenges in cellular therapy development and expedite the path to targeted cancer treatment.
Copyright © 2025 Alfa Cytology. All rights reserved.